We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BLAZE-1

News List

Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial expresspharma
March 11, 2021
Results support use of bamlanivimab 700 mg and etesevimab 1400 mg, the dose authorised in the US and several other countries.
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine worldpharmanews
November 06, 2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 ...